Advances in 2-substituted benzothiazole scaffold-based chemotherapeutic agents

Targeted therapy plays a pivotal role in cancer therapeutics by countering the drawbacks of conventional treatment like adverse events and drug resistance. Over the last decade, heterocyclic derivatives have received considerable attention as cytotoxic agents by modulating various signaling pathways. Benzothiazole is an important heterocyclic scaffold that has been explored for its therapeutic potential. Benzothiazole-based derivatives have emerged as potent inhibitors of enzymes such as EGFR, VEGFR, PI3K, topoisomerases, and thymidylate kinases. Several researchers have designed, synthesized, and evaluated benzothiazole scaffold-based enzyme inhibitors. Of these, several inhibitors have entered various phases of clinical trials. This review describes the recent advances and developments of benzothiazole architecture-based derivatives as potent anticancer agents.

Automated summary

Targeted therapy is crucial in cancer treatment, overcoming drawbacks of conventional therapy. Heterocyclic derivatives have gained attention as cytotoxic agents, with benzothiazole being explored for its therapeutic potential. Benzothiazole-based derivatives have emerged as potent inhibitors of enzymes, with some already in clinical trials. This review highlights recent advancements in benzothiazole-based derivatives as potent anticancer agents.